ArticleScientific reports2025
The impact of completely shrunken blastocysts on clinical outcomes in vitrified-warmed single blastocyst transfer cycles.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate whether blastocysts that do not re-expand 2–4 h after thawing were of value for utilization and to analyze the relevant factors affecting clinical pregnancy in completely shrunken blastocyst transfer (CSBT) cycles. The retrospective cohort study included 104 single embryo transfer cycles with CSBT and 2172 cycles with re-expanded blastocyst transfer (REBT). Confounders between groups were adjusted using propensity scoring matching. Clinical pregnancy rate (CPR), ongoing pregnancy rate (OPR), and live birth rate (LBR) were the primary outcome measures. In addition, patients’ characteristics were compared between the pregnancy and non-pregnancy groups in CSBT cycles. After matching, CPR (28.8% vs. 61.5%), OPR (22.1% vs. 52.9%), and LBR (20.2% vs. 50.0%) were significantly lower in the CSBT group than in the REBT group, P < 0.001. In CSBT cycles, pregnancy and non-pregnancy groups had significant differences in maternal age (29.4 ± 4.5 vs. 32.4 ± 6.0, P = 0.007), basal FSH (6.8 ± 2.0 vs. 8.0 ± 3.7, P = 0.029), blastocysts derived from good-quality day 3 embryos (63.3% vs. 32.4%, P = 0.004), and blastocysts formed day 5 (80.0% vs. 50.0%, P = 0.005). Binary logistic regression analysis identified the day of blastocyst formation as a significant determinant of pregnancy outcomes. The clinical pregnancy rate was 3.062 times higher for day 5 blastocysts compared to day 6 blastocysts in CSBT cycles (adjusted OR 3.062, 95% CI 1.077–8.704, P = 0.036). In conclusion, blastocysts which did not re-expand within 2–4 h post-thawing should not be considered non-viable. Although clinical pregnancy and live birth rates are significantly lower in completely shrunken blastocysts (CSBs) compared to re-expanded blastocysts (REBs), CSBs still retain implantation potential, particularly when derived from day 5 embryos.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.